Skip to main content
Rapid Dose Therapeutics Corp logo

Rapid Dose Therapeutics Corp — Investor Relations & Filings

Ticker · DOSE ISIN · CA75339A1012 CSE Manufacturing
Open in API
Filings indexed 490 across all filing types
Latest filing 2025-01-29 Interim / Quarterly Rep…
Country CA Canada
Listing CSE DOSE

About Rapid Dose Therapeutics Corp

https://rapid-dose.com/

Rapid Dose Therapeutics Corp. is a pharma-technology company specializing in proprietary drug delivery technologies engineered to enhance patient outcomes and quality of life. The core business revolves around an innovative oral delivery platform utilizing sublingual thin film strip technology. The company's flagship product, QuickStrip™, is a fast-dissolving system designed for the rapid release of pharmaceuticals, micronized oils, and over-the-counter medicines. QuickStrip™ is distinguished by its ability to achieve blood concentrations comparable to intravenous injection, offering superior bioavailability and rapid onset. RDT provides product innovation, production, and consultation services to the pharmaceutical and healthcare manufacturing sectors for both prescription and non-prescription applications.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for Rapid Dose Therapeutics Corp. for the period ending November 30, 2024. It contains comprehensive financial statements (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Changes in Equity, and Statement of Cash Flows) along with detailed notes to the financial statements. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2025
2025-01-29 English
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing a strategic collaboration extension (pre-commercialization agreement) for product development. It does not present financial results (ER/IR/10-K), management discussion (MDA), capital raising (CAP), M&A (TAR), governance changes (MANG), dividend (DIV), or any of the other specific categories. It is a general corporate announcement, so the appropriate fallback category is Regulatory Filings (RNS).
2025-01-29 English
News release - English.pdf
Share Issue/Capital Change Classification · 75% confidence The document is a press release announcing the issuance of common shares to settle debt and the decision not to proceed with a previously disclosed private placement. This constitutes an announcement of new share issuance and a capital structure change rather than an earnings release or routine regulatory report. It fits the definition of “Share Issue/Capital Change,” Code: SHA.
2025-01-27 English
Material change report - English.pdf
Capital/Financing Update Classification · 87% confidence The document is a press release announcing the closing of a non-brokered private placement financing: details of units issued, pricing, warrants, finder’s fees, use of proceeds, and regulatory hold periods. This is not a full financial report, audit, or AGM material, nor is it a share repurchase or dividend notice—it is a capital-raising announcement. Therefore, it fits the Capital/Financing Update category (CAP).
2025-01-27 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2025-01-24 English
Report of Distributions outside Canada (Form 72-503F).pdf
Regulatory Filings
2025-01-24 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.